®
Bella One PAP
®
The Bella One PAP is a FDA-approved test to screen for presence of human papillomavirus (HPV) DNA along with genotyping for high risk strains of HPV. The molecular panel also screens for presence of sexually transmitted infections and bacterial vaginosis pathogens that pose a threat to women's health
Bella One PAP Panel Menu
Performance: 100% sensitivity and 99.8% specificity
Sample Type: Cervical Vaginal
Methodology: Real-Time PCR
STI Molecular Assay Panel
BV Assay Molecular Panel
Chlamydia trachomatis
Trichomonas vaginalis
Neisseria gonorrhoeae
Mycoplasma genitalium
Mycoplasma hominis
Ureaplasma urealyticum
Ureaplasma parvum
Herpes simplex virus Type 1
Herpes simplex virus Type 2
Gardnerella vaginalis
Prevotella bivia
Atopobium vaginae
Mobiluncus curtisii
Bacteroides fragilis
Megasphaera Type 1
Pan–Lactobacillus
Bacterial vaginosis
Boost effectiveness of patient testing
Awareness about the link between HPV and cervical cancer has grown exponentially – leading to earlier detection and prevention. The CDC estimates that up to 93 percent of cervical cancers can be prevented. And yet, 33 percent of the 12,000 women who are diagnosed annually will die.
Why Bella One PAP?
The Bella One PAP screens for presence of Human Papilloma Virus (HPV) DNA as well as precancerous cells to determine whether a woman is at high-risk for developing cervical precancerous or cancerous conditions. – in addition Bella One Pap is design to test for a host of other infectious gynecological conditions.
Ultra Solutions
Molecular Reporting
For negative results PCG Molecular will send your patients an email on your behalf within 24 hours if patient results are negative for “watch” or high risk results. Being placed on a watch is no reason for patients to panic. It doesn’t mean they have cervical cancer or that they will ever get it. All it means is that we need to watch their cases more closely. We will send you a report and give you a sample letter to send to your patients that communicates the results and what next steps to follow. for positive results. You will receive a detailed report for those patients that test positive for oncogenic viral related sexually transmitted infections. These patients may require additional tests after treatment, along with a personal call. We can advise you of next steps and referrals if you need them.